NxStage Medical, Inc. (NASDAQ:NXTM) SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $24.16, for a total value of $103,888.00. Following the transaction, the senior vice president now owns 28,721 shares in the company, valued at approximately $693,899.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

NxStage Medical, Inc. (NXTM) traded down 1.68% during trading on Friday, hitting $23.93. The stock had a trading volume of 289,492 shares. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80. The stock has a 50 day moving average of $23.85 and a 200 day moving average of $26.03. The firm’s market capitalization is $1.57 billion.

NxStage Medical (NASDAQ:NXTM) last released its earnings results on Tuesday, May 9th. The medical device company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. NxStage Medical had a negative return on equity of 2.31% and a negative net margin of 1.25%. The business had revenue of $96.83 million during the quarter, compared to analysts’ expectations of $95.31 million. During the same quarter last year, the firm posted ($0.02) earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. Equities research analysts expect that NxStage Medical, Inc. will post ($0.03) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: NxStage Medical, Inc. (NXTM) SVP Sells 4,300 Shares of Stock” was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/21/insider-selling-nxstage-medical-inc-nxtm-svp-sells-4300-shares-of-stock.html.

Several equities analysts have recently weighed in on NXTM shares. Northland Securities reiterated a “buy” rating and set a $35.00 price objective on shares of NxStage Medical in a report on Monday, April 3rd. Canaccord Genuity reiterated a “buy” rating and set a $32.00 price objective on shares of NxStage Medical in a report on Monday, May 8th. BTIG Research reiterated a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a report on Wednesday, May 10th. Jefferies Group LLC cut their price objective on NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Finally, Craig Hallum started coverage on NxStage Medical in a report on Tuesday, June 27th. They set a “buy” rating and a $32.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. NxStage Medical presently has a consensus rating of “Buy” and a consensus price target of $30.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in NXTM. SG Americas Securities LLC purchased a new position in shares of NxStage Medical during the first quarter valued at about $140,000. Ameritas Investment Partners Inc. purchased a new position in shares of NxStage Medical during the first quarter valued at about $148,000. Quantitative Systematic Strategies LLC purchased a new position in shares of NxStage Medical during the second quarter valued at about $203,000. Menta Capital LLC purchased a new position in shares of NxStage Medical during the first quarter valued at about $212,000. Finally, Jane Street Group LLC purchased a new position in shares of NxStage Medical during the first quarter valued at about $213,000. Institutional investors and hedge funds own 95.28% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.